GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly ... many of the risk factors of a ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

Researchers identified 1924 recurrent nephrolithiasis events among 14,456 weighted patients who used an SGLT-2 inhibitor compared with 853 events among the 5877 patients who used a GLP-1 RA.

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...